Wanbury Limited has informed the Exchange regarding a press release dated August 06, 2025, titled "Press Release on Q1 26 Unaudited Financial Results".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wanbury Limited reported its Q1 FY26 consolidated results with revenue from operations at ₹163.2 crore, up 24% year-on-year from ₹131.1 crore in Q1 FY25. EBITDA (including other income) surged 108% YoY to ₹24.8 crore, with EBITDA margin expanding by 610 basis points to 15.2%. Profit after tax jumped to ₹13.5 crore from just ₹1.0 crore in Q1 FY25 — a 1,198% YoY increase — taking PAT margin to 8.3%. On a quarter-on-quarter basis, however, revenue declined 5%, EBITDA fell 21%, and PAT dropped 33% compared to Q4 FY25. Key business updates include the pan-India launch of C R ED RED (an anemia management product), GMP certification of its Patalganga and Tanuku API plants from Brazil's ANVISA, and a Board-approved ₹85 crore CAPEX plan for new APIs.
The sharp YoY jump in PAT and margin expansion signal a strong recovery year for Wanbury, though the QoQ moderation may temper near-term enthusiasm. Shareholders can view the new product launches, regulatory wins, and CAPEX approval as positive growth catalysts, while limited US exposure (~15% of exports) provides some insulation from tariff risks.